MARKET

BEAM

BEAM

Beam Therapeutics Inc.
NASDAQ
23.62
+0.50
+2.16%
After Hours: 24.00 +0.38 +1.61% 19:56 03/26 EDT
OPEN
23.15
PREV CLOSE
23.12
HIGH
24.59
LOW
22.76
VOLUME
2.30M
TURNOVER
--
52 WEEK HIGH
36.44
52 WEEK LOW
13.53
MARKET CAP
2.41B
P/E (TTM)
-29.2038
1D
5D
1M
3M
1Y
5Y
1D
Beam Therapeutics Is Maintained at Buy by Citigroup
Dow Jones · 17h ago
Beam Therapeutics Price Target Raised to $68.00/Share From $64.00 by Citigroup
Dow Jones · 17h ago
Citigroup Maintains Buy on Beam Therapeutics, Raises Price Target to $68
Benzinga · 17h ago
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pharmaceuticals (IONS)
TipRanks · 21h ago
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Beam Therapeutics (BEAM) and Cardiff Oncology (CRDF)
TipRanks · 21h ago
Beam Therapeutics (BEAM) Gets a Buy from Bernstein
TipRanks · 22h ago
Beam Therapeutics price target raised to $68 from $64 at Citi
TipRanks · 22h ago
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Maze Therapeutics, Inc. (MAZE) and Daiichi Sankyo Company (OtherDSKYF)
TipRanks · 22h ago
More
About BEAM
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

Webull offers Beam Therapeutics Inc stock information, including NASDAQ: BEAM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BEAM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BEAM stock methods without spending real money on the virtual paper trading platform.